Kamila Zawadzińska-Halat

Dr. Kamila Zawadzińska-Halat


Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
DZDominika Ziolkowska Dominika Ziolkowska
Dominika Ziolkowska Dominika Ziolkowska
MPMaciej Pastuszczak
Maciej Pastuszczak
KZKamila Zawadzińska-Halat
Kamila Zawadzińska-Halat
EHEwa Hadas
Ewa Hadas
ABAndrzej Bożek
Andrzej Bożek
Identifying immunologic predictors of clinical responses remains an unmet need in the era of biologic therapy for psoriasis. Super responders (SRs), defined as patients achieving complete skin clearance within weeks of treatment initiation, represent an emerging clinical endotype; however, their immunological profiles remain insufficiently characterized. We conducted a prospective observational study to characterize serum cytokine profiles associated with SR status in biologic-naïve patients with moderate-to-severe plaque psoriasis treated with secukinumab, an IL-17A inhibitor. Twenty-eight patients were enrolled and stratified at week 12 into SR (PASI = 0; n = 9) and non-super responder (NSR; PASI > 0; n = 19) groups. Serum concentrations of 19 cytokines were analyzed at baseline and after 12 weeks of treatment. SRs displayed a distinct immunological signature characterized by significantly higher IL-13 and lower IL-18 baseline levels compared to NSRs (p = 0.002 and p = 0.007, respectively), alongside reduced baseline monocyte counts. L1-regularized logistic regression confirmed IL-13 and IL-18 as strong independent predictors of SR status (AUC = 0.91). Moreover, the IL-18/IL-13 ratio emerged as a highly discriminative biomarker (p = 0.00001, AUC = 0.86). Notably, SRs exhibited a more pronounced decline in IL-18 and IL-23 during treatment. Our findings provide novel insights into the immunopathogenesis of super response and suggest that an immunological milieu favoring Th2 polarization may promote superior outcomes with IL-17A blockade. Incorporating IL-13, IL-18, and their ratio into clinical algorithms may facilitate precision-guided biologic therapy in psoriasis.

13 June 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
DZDominika Ziolkowska Dominika Ziolkowska
Dominika Ziolkowska Dominika Ziolkowska
MPMaciej Pastuszczak
Maciej Pastuszczak
KZKamila Zawadzińska-Halat
Kamila Zawadzińska-Halat
EHEwa Hadas
Ewa Hadas
ABAndrzej Bożek
Andrzej Bożek
Identifying immunologic predictors of clinical response remains an unmet need in the era of biologic therapy for psoriasis. Super responders (SRs), defined as patients achieving complete skin clearance within weeks of treatment initiation, represent an emerging clinical endotype; however, their immunological underpinnings are poorly understood. We conducted a prospective observational study to characterize serum cytokine profiles associated with SR status in biologic-naïve patients with moderate-to-severe plaque psoriasis treated with secukinumab, an IL-17A inhibitor. Twenty-eight patients were enrolled and stratified at week 12 into SR (PASI = 0; n = 9) and non-super responder (NSR; PASI > 0; n = 19) groups. Serum concentrations of 19 cytokines were analyzed at baseline and after 12 weeks of treatment. SRs displayed a distinct immunological signature characterized by significantly higher IL-13 and lower IL-18 baseline levels compared to NSRs (p = 0.002 and p = 0.007, respectively), alongside reduced baseline monocyte counts. L1-regularized logistic regression confirmed IL-13 and IL-18 as strong independent predictors of SR status (AUC = 0.91). Moreover, the IL-18/IL-13 ratio emerged as a highly discriminative biomarker (p = 0.00001, AUC = 0.86). Notably, SRs exhibited a more pronounced decline in IL-18 and IL-23 during treatment. Our findings provide novel insights into the immunopathogenesis of super response and suggest that an immunological milieu favoring Th2 polarization may promote superior outcomes with IL-17A blockade. Incorporating IL-13, IL-18, and their ratio into clinical algorithms may facilitate precision-guided biologic therapy in psoriasis.

16 October 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
DZDominika Ziolkowska Dominika Ziolkowska
Dominika Ziolkowska Dominika Ziolkowska
KZKamila Zawadzińska-Halat
Kamila Zawadzińska-Halat
PBPaulina Ewa Basta
Paulina Ewa Basta
MPMaciej Pastuszczak
Maciej Pastuszczak
Introduction: Super responders (SRs)—patients achieving complete skin clearance (PASI = 0) soon after biologic initiation—represent a clinically relevant but underexplored phenotype. This study is one of the first real-world, multi-agent analyses comparing SR likelihood across biologic classes in plaque psoriasis. We assessed whether biologic choice predicts SR in routine clinical practice. Methods: We performed a retrospective, single-center study of 116 adults with moderate-to-severe plaque psoriasis initiating their first biologic (adalimumab, tildrakizumab, guselkumab, risankizumab, bimekizumab, or secukinumab). SR was defined as PASI = 0 at week 12. SR proportions (exact 95% CIs) were compared using Fisher’s exact tests and odds ratios (ORs). Multivariable logistic regression estimated adjusted associations between biologic and SR, controlling for age, sex, disease duration, BMI, baseline PASI, and prior cyclosporine/acitretin. Sensitivity analyses included Firth bias-reduced regression, the exclusion of sparse drug strata, and an alternative endpoint (PASI ≤ 1 at week 12). Results: Overall, 26/116 patients (22.4%) achieved SR. SR proportions differed by agent, highest with bimekizumab (11/17; 64.7%); Fisher’s p < 0.001 vs. others; OR = 12.83 (95% CI 4.17–39.50). In adjusted models, bimekizumab remained independently associated with SR (adjusted OR = 17.30; 95% CI 4.62–64.82; p = 2.35 × 10−5), while other covariates were not significant. Conclusions: In this real-world cohort, biologic selection—particularly bimekizumab—was the main determinant of early complete clearance. These findings highlight mechanistic class as a key driver of rapid, deep responses and support prospective validation with harmonized SR definitions and extended follow-up.

8 September 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
MPMarta Pośpiech
Marta Pośpiech
KZKamila Zawadzińska-Halat
Kamila Zawadzińska-Halat
MPMaciej Pastuszczak
Maciej Pastuszczak
Introduction: Seborrheic dermatitis (SD) is a lipid-dependent inflammatory dermatosis in which sebaceous activity, Malassezia, barrier dysfunction and host inflammation interact. Whether scalp SD severity is associated with systemic lipid and liver-associated biochemical parameters remains unclear. Methods: In this exploratory cross-sectional observational study, we included 34 adults with clinically diagnosed scalp SD. Severity was assessed using a published 16-point scalp SD score and a study-specific 0–36 physician-assessed score. Fasting lipids, glucose, alanine aminotransferase (ALT), aspartate aminotransferase and gamma-glutamyl transferase (GGT) were recorded. The triglyceride/high-density lipoprotein cholesterol ratio and non-HDL cholesterol were calculated. Patients were stratified as having non-severe or severe disease according to the 16-point score. Results: Complete 16-point data were available in 33 patients: 15 with non-severe and 18 with severe scalp SD. Severe disease was associated with higher triglycerides (116.0 vs. 78.0 mg/dL; p = 0.004), triglyceride/high-density lipoprotein cholesterol ratio (2.57 vs. 1.23; p = 0.006), ALT (46.0 vs. 20.0 U/L; p = 0.028) and GGT (33.0 vs. 11.0 U/L; p = 0.003). The strongest correlations with the 16-point score were observed for GGT (rho = 0.745), triglycerides (rho = 0.634), ALT (rho = 0.572) and triglyceride/high-density lipoprotein cholesterol ratio (rho = 0.569; all p < 0.001). These prespecified associations remained significant after false-discovery-rate adjustment and after adjustment for age and BMI. The correlation pattern was strengthened using the 0–36 score and persisted after excluding one liver enzyme outlier. Conclusions: More severe scalp SD was associated with triglyceride-related lipid parameters and liver-associated enzymes, suggesting a broader lipid-liver metabolic phenotype. These findings require confirmation in larger controlled studies.